Decatur Capital Management Inc. reduced its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 157,700 shares of the biopharmaceutical company’s stock after selling 24,775 shares during the quarter. Bristol-Myers Squibb makes up about 2.0% of Decatur Capital Management Inc.’s portfolio, making the stock its 25th biggest holding. Decatur Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $9,664,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Advisor Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after acquiring an additional 2,382 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Bristol-Myers Squibb by 2.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after acquiring an additional 8,813 shares during the period. Israel Discount Bank of New York boosted its stake in shares of Bristol-Myers Squibb by 31.8% during the 2nd quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after acquiring an additional 2,540 shares during the period. Van ECK Associates Corp boosted its stake in shares of Bristol-Myers Squibb by 0.7% during the 3rd quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock worth $50,436,000 after acquiring an additional 5,451 shares during the period. Finally, Aperio Group LLC boosted its stake in shares of Bristol-Myers Squibb by 12.7% during the 3rd quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock worth $54,463,000 after acquiring an additional 96,561 shares during the period. Institutional investors own 71.55% of the company’s stock.
Several analysts recently weighed in on BMY shares. ValuEngine cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Bank of America lifted their price target on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a report on Monday, March 5th. Jefferies Group set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, February 26th. Finally, DZ Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $66.30.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 EPS. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.2 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.40%. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
In related news, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/bristol-myers-squibb-co-bmy-shares-sold-by-decatur-capital-management-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.